Clinical Trials List
2021-01-01 - 2024-12-31
Phase II
Recruiting5
ICD-10C34.2
Malignant neoplasm of middle lobe, bronchus or lung
ICD-10C7A.090
Malignant carcinoid tumor of the bronchus and lung
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9162.4
Malignant neoplasm of middle lobe, bronchus or lung
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/04/01
Investigators and Locations
Co-Principal Investigator
- 徐偉勛 Division of Hematology & Oncology
- CHAO-CHI HO CHAO-CHI HO Division of General Internal Medicine
- 楊景堯 Division of General Internal Medicine
- 廖斌志 Division of Hematology & Oncology
- 廖唯昱 Division of General Internal Medicine
- 吳尚俊 Division of General Internal Medicine
- James Chih-Hsin Yang Division of General Internal Medicine
- Chong-Jen Yu Division of General Internal Medicine
- 蔡子修 Division of General Internal Medicine
- YEN-TING LIN Division of General Internal Medicine
- Jih-Hsiang Lee Division of Hematology & Oncology
- JIN-YUAN SHIH Division of Thoracic Medicine
- 許嘉林 Division of General Internal Medicine
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- YEN-HSIANG HUANG Division of Thoracic Medicine
- KUO-HSUAN HSU Division of Thoracic Medicine
- JENG-SEN TSENG Division of Thoracic Medicine
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 邱建通 Division of Thoracic Medicine
- 陳鍾岳 Division of Thoracic Medicine
- 吳俊廷 Division of Thoracic Medicine
- 許棨逵 Division of Thoracic Medicine
- Ming-Shyan Huang Division of Thoracic Medicine
- 李和昇 Division of Thoracic Medicine
- 陳俊榮 Division of Thoracic Medicine
- 賴永發 Division of Thoracic Medicine
- 周柏安 Division of Thoracic Medicine
- 陳靜宜
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
5-10 participants
-
Global
46 participants